Allergy/Imm

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Gofrit ON et al. - In a trial to explore patterns of recurrence, muscle invasion, and disease-specific mortality in pts with bladder carcinoma in situ (CIS) who responded to an induction course with intravesical bacillus Calmette-Gúerin (BCG) immunotherapy, it was shown that pure and concomitant bladder CIS share similar biologic behavior. Muscle-invasive disease is expected in about 25% of BCG responders followed for long time periods and disease-specific mortality in 15%. Tumor recurrence, whether nonmuscle-invasive or muscle-invasive, follows a similar time table suggesting that these are not sequential but parallel and independent processes.

Methods

Results


Today in Hematology/Oncology...keeping you current

Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance
Journal of Clinical Oncology, 10/23/09

Update of the guidelines for lupus anticoagulant detection
Journal of Thrombosis and Haemostasis, 09/28/09

Romiplostim in chronic immune thrombocytopenic purpura
Clinical Therapeutics, 10/23/09

Today in Vaccine/Immunotherapy...keeping you current

Update on vaccination guidelines for allergic children
Expert Review of Vaccines, 10/29/09

Does BCG vaccination protect against the development of childhood asthma? A systematic review and meta-analysis of epidemiological studies
International Journal of Epidemiology, 10/14/09

Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the age of remission?
Expert Opinion on Investigational Drugs, 10/13/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address